Perioperative management of patients receiving longterm antithrombotic therapy. Clinical guidelines


Cite item

Full Text

Abstract

The guidelines present approaches to indication and interruption of long-term antithrombotic and anticoagulant therapy in perioperative period, as well as current concepts of performing regional anesthesia in patients, receiving antithrombotic and anticoagulant therapy. The guidelines are based on the Guidelines, issued by European Society of Anesthesiology, 2010, and analytical overview of recommendations of various national societies of regional anesthesia.

About the authors

Igor B. Zabolotskih

SBEI “Kuban State Medical University” of MHC of RF

Email: pobeda_zib@mail.ru
350063, Krasnodar

M. Yu Kirov

SBEI "North State Medical University” of MHC of RF

163000, Arckhangelsk

S. A Bozhkova

FSBI “Vreden Russian Research Institute of Traumatology and Orthopedics” of MHC of RF

195427, Saint Petersburg

A. Yu Bulanov

FSBI “Hematological Research Center” of MHC of RF

125167, Moscow

N. A Vorob'yova

SBEI "North State Medical University” of MHC of RF

163000, Arckhangelsk

E. V Grigoriev

SBEI “Kemerovo State Medical Academy” of MHC of RF

650056, Kemerovo

A. I Gritsan

SBEI “Krasnoyarsk State Medical University” of MHC of RF

660022, Krasnoyarsk

I. S Kurapeev

SBEI “Mechnikov North-West State Medical University" of MHC of RF

191015, Saint Petersburg

K. M Lebedinskiy

SBEI “Mechnikov North-West State Medical University" of MHC of RF

191015, Saint Petersburg

V. V Lomivorotov

FSBI “Academician Meshalkin Novosibirsk Research Institute of Circulation pathology”

630055, Novosibirsk

A. M Ovechkin

SBEI “Sechenov First Moscow State Medical University” of MHC of RF

119991, Moscow

V. I Potievskaya

SBEI “Russian Medical Academy of Postgraduate Education” of MHC of RF

123995, Moscow

S. V Sin’kov

SBEI “Kuban State Medical University” of MHC of RF

350063, Krasnodar

V. V Subbotin

FSBRI “Academician Petrovskiy Russian Research Center of Surgery” of MHC of RF

119991, Moscow

E. M Shulutko

FSBI “Hematological Research Center” of MHC of RF

125167, Moscow

References

  1. Заболотских И.Б., Синьков С.В., Мусаева Т.С. Периоперационное ведение больных, длительно получающих антитромботические препараты. - В кн.: Периоперационное веденеи больных с сопутствующими заболеваниями. Том 1 (под ред. Заболотских И.Б.). Москва, 2011.
  2. Затейщиков Д.А., Зотова И.В.,, Данковцева Е.Н., Сидоренко Б.А. Тромбозы и антитромботическая терапия при аритмиях. М.: «Практика», 2011.
  3. Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Рабочая группа по подготовке текста рекомендаций под председательством проф. Панченко Е.П. Кардиоваскулярная терапия и профилактика. 2009; 8 (6), Приложение 6.
  4. Оганов Р.Г., Мамедов М.Н. Всероссийское научное общество кардиологов. Национальные клинические рекомендации. М.:, Меди ЭКСПО, 2009.
  5. Отраслевой стандарт «Протокол ведения больных. Профилактика тромбоэмболии легочной артерии при хирургических и иных инвазивных вмешательствах» Профилактика тромбоэмболических осложнений у хирургических больных в многопрофильном стационаре: Методические рекомендации. Под ред. Ю.Л. Шевченко и В.С. Савельева. М.: Издательство «Ньюдиамед», 2004.
  6. Профилактика венозных тромбозов и тромбоэмболии легочной артерии. Рекомендации Всероссийской Ассоциации по изучению тромбозов, геморрагий и патологии сосудов имени А.А. Шмидта - Б.А. Кудряшова и Всероссийского общества флебологов. Москва, 2011 г.
  7. Рекомендации по диагностике и лечению тромбоэмболии легочной артерии Европейского общества кардиологов. Рациональная Фармакотерапия в Кардиологии. 2009; 1-2.
  8. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010; 4 (1): 2-37.
  9. Тромбоэмболия легочной артерии: руководство. Под ред. С.Н. Терещенко. М.: Гэотар-Медиа, 2010.
  10. Чарная М.А., Морозов Ю.А. Тромбозы в клинической практике. М: Гэотар-Медиа, 2009.
  11. Albaladejo P., Marret E., Samama C.M. et al. Non-cardiac surgery in patients with coronary stents: the RECO study. Heart. 2011; 97: 1566-1572.
  12. Ansell J., Hirsh J., Poller L. et al. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP conference on Antithrombotic and Thrombolytic Therapy. Thest. 2004; 126: 204-233.
  13. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (2, suppl.): 1-801.
  14. Blanc J.J., Almendral J., Brignole M. et al. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. Eurospace. 2008; 10: 513-527.
  15. Bornemann H., Pluller F., Metzler H. The patient with coronary stents and antiplatelet agents: what to do and how to deal. European Journal of Anaesthesiology. 2010; 27 (5): 406-410.
  16. Despotis G.J., Skubas N.J., Goodnough L.T. Optimal management of bleeding and transfusion in patients undergoing cardiac surgery. Semin Thorac Cardiovasc Surg. 1999; 11: 84-104.
  17. Douketis J.D., Johnson J.A., Turpie A.G. Low-molecular-weight heparin as bridging anticoagubation during interruption of warfarin: Assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004; 164: 1319-1326.
  18. Douketis J.D. Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: A practical guide for clinicians. Thromb Res. 2002; 108: 3-13.
  19. Dunn A.S., Turpie A.G. Perioperative management of patients receiving oral anticoagulants: A systematic review. Arch Intern Med. 2003; 163: 901-908.
  20. Gogarten W., Van Aken H., Buttner J., Riess H., Wulf H., Buerkle H. Riickenmarksnahe Regionalanasthesien und Thromboembolieprophylaxe / antithrombotische Medikation. Uberarbeitete Leitlinien der Deustchen Gesellschaft fiir Anasthesiologie und Intensivmedizin. And'sth Inten sivmed. 2003; 44: 218-230.
  21. Gogarten W., Vandermeulen E., Aken H.V., Kozek S., Llau J.V., Samamа C.M. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010; 27: 999-1015.
  22. Health Care Guideline: Antithrombotic Therapy Supplement. Institute for Clinical Systems Improvement, Eleventh Edition February. 2013. [Электронный ресурс]. - Режим доступа: https://www.icsi.org/_asset/bjr47w/Antithrombo.pdf.
  23. Heit T.A. Perioperative management of the chronically anticoagulated patient. J Thromb Thrombolysis. 2001; 12: 81-87.
  24. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126: 188-203.
  25. Horlocker T.T., Heit J.A. Neuraxial block and the anticoagulated patient: balancing the risk and benefits. In: Kitchens C.S., ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company; 2004: 589-598.
  26. Horlocker T.T., Wedel D.J., Rowlingson J.C. et al. Regional anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy (American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines, Third Edition). Reg Anesth Pain Med. 2010; 35: 102-105.
  27. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997; 336: 1506-1511.
  28. Kovacs M.J., Kearon C., Rodger M. et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004; 110: 1658-1663.
  29. Kozek-Langenecker S.A. et al. Management of severe perioperative bleeding. Eur J Anaesthesiol. 2013; 30:270-382.
  30. Kozek-Langenecker S.A., Fries D., Giitl M. et al. Lokor- egionalanasthesien unter gerinnungshemmender Medikation. Anaestbesist. 2005; 54: 476-484.
  31. Lecompte T., Hardy J. Antiplatelet agents and perioperative bleeding. Canadian Journal of Anaesthesia. 2006; 53: S103-S112.
  32. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010; 137 (2): 263-272.
  33. Llau J.V., De Andres J., Gomar C. et al. Anticlotting drugs and regional anaesthetic and analgesis technigues: comparative update of the safety recommendatios. European Journal of Anaesthesiology. 2007; 24: 387-398.
  34. Llau Pitarch J.V., De Andres Ibafiez J., Gomar Sancho C., Gomez Luque A., Hidalgo Martinez F., Torres Morera L.M. Guidelines of hemostasis inhibiting drugs and neuraxial anaesthesia (Spanish). Rev Esp Anestesiol Reanim. 2005; 52: 413-420.
  35. Metzler H. Antiplatelet therapy and coronary stents in perioperative medicine - the two sides of the coin. Best Practice and Research Anaesthesiology. 2008; 22 (1): 81-94.
  36. Palareti G., Legnani C. Warfarin withdrawal: Pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet. 1996; 30: 300-313.
  37. Salem D.M. et al. Valvular and structural heart desease. Chest. 2008; 133: 593-629.
  38. Serebruany V.L., Malinin A.l., Eisert R.M., Sane D.C. Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004; 75: 40-47.
  39. Siber S., Albertsson P., Aviles F.F., Camici P.G. Guidelines for pecutaneous coronary intervrntions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. European Heart Journal. 2005; 26: 804-847.
  40. Sie P., Samama C.M., Godier A. et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis. Arch Cardiovasc Dis 2011; 104: 669-676.
  41. Singer D.E. et al. Antithrombotic therapy in atrial fibrillation. Chest. 2008; 133: 546-592.
  42. Smith S.C., Feldman T.E., Hirshfeld J.W., Jacobs A.K. ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology. 2006; 47: 216-235.
  43. Van Ryn J., Litzenburger T., Waterman A. et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to Dabigatran in vitro and in vivo models. JACC 2011; 57: E1130.
  44. Vandermeulen E., Singelyn F., Vercauteren M., Brichant J. F., Ickx B. E., Gautier P. Belgian guidelines concerning central neural blockade in patients with drug induced alteration of coagulation: an update. Acta Anaesthesiol Belg. 2005; 56: 139-146.
  45. Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
  46. White R.H., Mc. Kittrick T., Hutchinson R., Twitchell J.: Temporary discontinuation of warfarin therapy: Changes in the international normalized ratio. Ann Intern Med. 1995; 122: 40-42.
  47. Wijns W., Kolh Ph., Danchin N. et al. Guidelines on myocardial revascularization. Eur. J. Cardiothorac. Surg. 2010; 38 (Suppl.): 1-52.
  48. Yusuf S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-elevation. N Engl О Med. 2001; 345: 494-502.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies